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Abstract 
Scaffolds for bone tissue engineering should be designed to optimize cell migration, 
enhance new bone formation and give mechanical support. In the present study, we 
used polycaprolactone-tricalciumphosphate (PCL/TCP) scaffolds with two different 
fibre lay down patterns which were coated with hydroxyapatite and gelatine as an 
approach for optimizing bone regeneration in a critical sized calvarial defect. After 12 
weeks bone regeneration was quantified using microCT analysis, biomechanical 
testing and histological evaluation. Notably, the experimental groups containing 
coated scaffolds showed lower bone formation and lower biomechanical properties 
within the defect compared to the uncoated scaffolds. Surprisingly, the different lay 
down pattern of the fibres resulted in different bone formation and biomechanical 
properties; namely 0/60/120° scaffolds revealed lower bone formation and 
biomechanical properties compared to the 0/90° scaffolds in all the experimental 
groups. The different architecture of the scaffold fibres may have an effect on 
nutrition supply as well as the attachment of the newly formed matrix to the scaffold. 
Therefore, future bone regeneration strategies utilising scaffolds should consider 
scaffold architecture as an important factor during the scaffold optimisation stages in 
order to move closer to a clinical application.  
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1. Introduction 
In general, bone is a dynamic and multifunctional organ, capable of good healing 
and remodelling capacities. However, in certain cases, surgical therapeutic 
intervention is required due to a limited intrinsic regeneration potential1. Beside the 
conventional surgical procedures, the concept of tissue engineering has emerged as 
an important approach to bone regeneration research. There are two major bone 
tissue engineering approaches to develop novel treatment concepts involving 
scaffolds: cell-based and cell-free. Scaffolds serve as space holders for cells and 
allow in-growth of host tissues into the reconstruction site after transplantation. Thus, 
they provide structures that facilitate the three-dimensional proliferation, 
differentiation and orientation of cells in order to enable tissue-like growth in vivo. 
Scaffolds facilitate the transfer of loads to surrounding tissues and preferably allow 
the reconstruction site to be mechanically competent directly after insertion. 
Scaffolds also provide a space in which tissue development and maturation towards 
complex multi-cellular systems can occur.  
The properties of a material’s surface can directly influence single cell behaviour, in 
the same way the three-dimensional structure plays a critical role in the orchestration 
of tissue formation in vivo. Surface properties and microstructure of a material refers 
to the material at the nanoscale or microscale level, whereas scaffold architecture 
defines the structure of the biomaterial in space at a tissue-length scale. Scaffolds 
not only provide the structural basis for cells to form a three-dimensional tissue-like 
construct in vivo, but they also influence the vascularity.  
To improve the mechanical and biochemical properties of the scaffolds, calcium 
phosphate ceramic particles have been mixed into the polymer phase directly2, 3. 
However, an important aspect which has been neglected in the context of bone 
tissue engineering is the interfacial properties between the ceramic and matrix 
phases, and therefore, limited improvements have been seen regarding the 
mechanical properties of polymer/ceramic composite scaffolds compared to 
polymeric scaffolds. Furthermore, the masking of the ceramic particles by a very thin 
polymer layer on the scaffold surface by the so called “skinning effect” may diminish 
the proliferative and osteoconductive properties offered by some bioactive ceramic 
particles4-6. 
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Hence, to improve the proliferative and osteoconductive properties of 
polymer/ceramic composite scaffolds, coating the scaffolds with a layer of 
mineralised apatite deposit is considered an efficient approach. In this context, to 
improve the mechanical properties of the polymer/ceramic composite scaffolds we 
have developed silanized polycaprolactone/tricalciumphosphate (PCL/TCP(si)) 
scaffolds, which have significantly improved mechanical properties compared to 
standard PCL/TCP scaffolds. Moreover, to improve the osteoconductive properties 
of the PCL/TCP(si) scaffolds, biomimetic coating were applied. The developed 
biomimetic apatite coated PCL/TCP(si) showed excellent mechanical properties and 
promising proliferative and osteoconductive properties in vitro7. Although, it is well 
known that the internal pore size and the architecture of the scaffolds influence the 
capability for bone regeneration, the optimal properties are still much debated8, 9. 
The effect of different lay down patterns has been conducted in terms of mechanical 
and in vitro characterization10-12. However, the effect of different lay down pattern on 
bone regeneration in an in vivo model has not yet been tested. 
 
To address these issues, in the present study, we investigated the use of silanized 
polycaprolactone/tricalciumphosphate (PCL/TCP(si)) scaffolds and carbonated 
hydroxyapatite coated scaffolds (PCL/TCP(si)-CHA) as an approach for optimizing 
the bone regenerative capabilities of the respective scaffolds in a critical sized 
calvarial defect model. Furthermore, in conjunction with the apatite coating, whilst 
keeping the overall porosities the same, we have analysed the effect of two different 
lay down patterns of the scaffolds, namely 0-60° and 0-90°, on bone regeneration 
capabilities. 
We hypothesized that the scaffolds would provide a suitable substrate for cell 
proliferation and osteogenic differentiation in vivo. 
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2. Material and Methods  
2.1. Materials 
Poly(ε-caprolactone) (PCL) (Mn: 80,000), 3-glycidoxypropyl trimethoxysilane 
(GPTMS), acetic acid (CH3COOH), calcium chloride (CaCl2), potassium 
hydrophosphate (K2HPO4), phosphoric acid (H3PO4, 85% solution in water), sodium 
carbonate (Na2CO3) and sodium hydroxide (NaOH) were purchased from Sigma-
Aldrich, Singapore. Tri-calcium phosphate (TCP) was purchased from Progentix, The 
Netherlands. 
 
 
2.2. Scaffold fabrication 
PCL/TCP(si) composite was synthesized as previously reported7. In brief, surface 
activation of TCP was achieved using phosphoric acid at room temperature for 2 hr. 
The surface activated TCP was then washed with distilled water, and GPTMS (4 
wt% of TCP) was added into TCP solution and refluxed at 75 ºC for 24 hr. The 
GPTMS modified TCP (TCP(si)) was collected by filtration and the washed TCP(Si) 
was incorporated into PCL solution through homogenization. The homogenized 
composite was dried and finally annealed to give PCL/TCP(si) composite. 
PCL/TCP(si) scaffolds were fabricated using an in house screw extrusion system 
(SES) with screw rotational speed of 25 rpm and nozzle diameter of 0.3 mm at 
processing temperature of 85 ºC. The scaffolds were fabricated with a size of 5 mm 
in diameter and 2 mm in thickness and two different laydown patterns, namely 0º/90º 
and 0º/60º/120º (Figure 1 A/B). The final composition for the scaffold fabrication was 
PCL (80%wt) and TCP (20%wt). Scaffolds used in this study showed similar 
characteristics with a porosity of 67-71%, a pore size of 420-500µm, and a scaffold 
surface area of 65-73mm2. 
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Fig. 1: 3D microCT reconstruction of the scaffolds 
showing the two different laydown patterns of the fibers 
(A/B, bar=1mm). SEM images showing the unmodified 
surface of the scaffold fibers (C, bar=10µm) and the 
hydroxyapatite coated surface of the scaffold fibres (D, 
bar=1µm). 
 
 
2.3. Surface coating on scaffolds 
The fabricated PCL/TCP scaffolds were first treated in 10 ml of 5 M NaOH at room 
temperature for 12 h, followed by thorough washing with deionised water to remove 
residual NaOH. The NaOH-treated scaffolds were then dipped alternately into 
calcium chloride solution and potassium hydrophosphate solution to obtain a 
CaHPO4 coating as a nucleation site for the next CHA coating13. In brief, the NaOH-
treated scaffolds were dipped in 20 ml of 0.2 M aqueous CaCl2 solution for 10 min 
and then dipped in deionised water for 5 s, followed by air drying for 3 min. The 
sample was subsequently dipped in 20 ml of 0.2 M aqueous K2HPO4 solution for 10 
min and then dipped in deionised water for 5 s, followed by air drying for 3 min. The 
whole process was repeated three times. The CaHPO4-coated scaffolds were 
immersed in 20 ml of 0.1 M CH3COOH and then 10 ml of 0.1 M CaCl2 and 6 ml of 
0.1 M H3PO4 (Ca/P = 1.66) were dropped slowly through separate syringe pumps 
under stirring. The pumps were adjusted to keep the ratio of Ca/P at 1.66. After 
further stirring for 30 min, 18 ml of 0.1 M Na2CO3 with the molar ratio of CO3/PO4 = 
3 was gradually added. The mixture was stirred for a further 30 min and then the pH 
of the mixture was adjusted to 9 using 1 M NaOH. The CHA-coated PCL/TCP 
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scaffolds (PCL/TCP–CHA) were collected after ageing the solution for 3 h. Finally, 
the scaffolds were thoroughly washed with deionised water and freeze dried (Fig. 1 
C/D).  
 
 
2.4. Animal Surgery 
Fifteen skeletally matured male Lewis rats were obtained from Animal Resources 
Centre, Canning Vale, WA. The rats were housed at the QUT Medical Engineering 
Research Facility (MERF) at the Prince Charles Hospital, Chermside. The animals 
received water and pelleted ration ad libitum throughout the experiment. The animal 
ethics committee of the University of Queensland approved all experiments. The rats 
were subjected to critical sized bone defect creation in their skull and implantation of 
the PCL/TCP(si) scaffolds. For each treatment group including the positive control 
group, two different laydown patterns of the scaffolds were used. Accordingly, the 
rats were assigned to five groups of six, as follows:  
Experimental Groups Pattern: 0/60°/120° Pattern: 0/90° 
PCL/TCP(si) (positive control group) n = 6 n = 6 
PCL/TCP(si)-CHA n = 6 n = 6 
Empty control group (n=6) -- -- 
Table 1: The five experimental groups of the study. Every group consists of 6 animals. 
 
 
2.5. Surgical procedure  
All rats were operated under general anaesthesia. Buprenorphine (0.01 - 0.05 mg/kg 
subcutaneously) were used pre-operatively for pre-emptive analgesia and post-
operatively every 6-12 hour as painkiller. General anaesthesia was provided using 
mixture of Ketamine and Xylazine (75-100 mg/kg Ketamine + 5-10 mg/kg Xylazine 
intraperitoneal in same syringe). Rats were handled briefly by hand for 
intraperitoneal injection of anaesthetic and then released into a separate cage until 
ready for surgery. The frontoparietal region was prepared by clipping hair with a 
delicate clipper and vigorous disinfection was achieved by application of 
chlorhexidine in alcohol solution. One dose of broad-spectrum antibiotic was given to 
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the rats before surgery as prophylaxis. In order to produce critical size bone defects, 
a sagittal incision of approximately 20 mm was performed over the scalp of the 
animal. A full-thickness bone defect (5 mm in diameter) was then trephined in the 
centre of each parietal bone (two defects per calvaria) using a slow speed dental drill 
with irrigation to prevent heat damage of the host bone. Caution was taken, when 
drilling down the bone, not to damage the underlying exposed dura mater (Figure 2). 
A strip 2-mm wide of the marginal periosteal surrounding the defect was then 
removed. According to the implantation plan, both bone defects in each rat were 
implanted with one of the treatment modalities described above. During anaesthesia, 
surgery and immediate post-operative period, the rats were kept warm on a heating 
pad and after that, they were transferred to a clean warmed cage for recovery.  
Animals were kept for 12 weeks after surgery and then sacrificed by CO2 inhalation. 
To collect the implants, the skin was dissected and the entire skull containing the 
defects/scaffolds were removed for further analysis.  
 
 
 
  
 
 
 
 
 
Fig. 2: The scull defects were drilled with a 5mm dental drill (A), the bone and the 
surrounding periosteum were carefully removed without damaging the dura (B) and the 
scaffolds were press fitted with good contact between the host bone and the scaffold (C).  
This was evident from the explanted specimens which showed excellent scaffold integration 
into the host bone with no fibrous capsule evident at 12 weeks in either the 0/90° laydown 
pattern group (D) and the 0/60/120° laydown pattern group (E). 
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2.6. Microcomputed tomography (MicroCT) 
Twelve weeks after surgery mineralization within the constructs was quantified using 
a Micro-CT 40 scanner (Scanco Medical, Brüttisellen, Switzerland). Samples were 
scanned at an energy of 55 kVp and intensity of 145 µA with 226 ms integration time, 
resulting in an isotropic voxel size of 36 μm. From the scanned volume, a cylindrical 
region of interest (ROI), corresponding to the defect size of 5 mm diameter and at 
the location of the original defect was selected for analysis. After segmentation of the 
mineralised tissue with a threshold of 220 (equivalent to 312 mgHA/ccm), a Gauss 
filter width of 0.8 and filter support of 1.0, the mineralized matrix volume, was 
quantified throughout the entire construct and presented as bone volume in mm3.  
 
 
 
 
 
2.7. Mechanical testing 
After microCT analysis, the samples were wrapped in wet gauze and stored at          
-20 C° until further analysis. Upon thawing, the rat skulls were potted into petri 
dishes with polymethylmethacrylate bone cement (Meliodent Rapid Repair, Heraeus 
Kulzer) to enable stable fixation for the mechanical testing. Non-destructive micro-
compression on the calvaria defects was performed using a Micro Tester 5848 
(Instron) with a 10-N load cell. An indenter probe was micro-fabricated for the test. 
Micro-compressions of up to 50% strain were conducted at an average of eight 
different locations on each defect site, and the load-displacement and stiffness 
(compression modulus) were determined. The probe locations were identified to be 
the pore spaces (between the scaffold struts) of the constructs to measure the 
modulus of regenerated tissue rather than scaffold material. Intact calvarial bone, 
soft tissue and the struts of the scaffolds were used as controls. Push-out tests were 
then conducted to evaluate the functional mechanical integration of the tissue-
engineered constructs into the host calvaria, and were performed on the Micro 
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Tester 5848 (Instron) with a 1-kN load cell14,15. An indenter probe of 4.5 mm 
diameter, slightly smaller than the scaffold diameter of 5 mm, was fabricated for the 
test. Four to six specimens were used for each group.  
 
2.8. Histology/Immunhistochemistry 
For processing decalcified samples into paraffin, parietal bone was fixed in 10% 
neutral buffered formalin for 24 h and decalcified in 15% EDTA for 3 weeks at 4 °C. 
The samples were then serially dehydrated in ethanol in a tissue processor 
(Excelsior ES, Thermo Scientific, Franklin, MA, USA), and embedding in paraffin. 
Sections (5 µm) were taken using a microtome (Leica RM 2265). The slides were 
then deparaffinized with xylene and rehydrated with serial concentrations of ethanol, 
before being stained with haematoxylin and eosin (Sigma Aldrich) and mounted with 
Eukitt mountant (Fluka Biochemica, Milwaukee, WI, USA).  
For immunohistochemistry, sections were deparaffinised with xylene and rehydrated 
with serial concentrations of ethanol. Subsequently, sections were rinsed in distilled 
water and placed in 0.2 M Tris-HCl buffer (pH 7.4). Endogenous peroxidase activity 
was blocked by incubating the sections in 3% H2O2 in Tris-HCl for 20 min. This was 
followed by three washes with Tris buffer (pH 7.4) for 2 min each. Sections were 
incubated with Proteinase K (DAKO, Botany, Australia) for 20 min and subsequently 
incubated with 2% bovine serum albumin (BSA) (Sigma, Sydney, Australia) in DAKO 
antibody diluent (DAKO) in a humidified chamber at room temperature for 20 min to 
block nonspecific binding sites. Afterwards, immunohistochemical staining was 
performed using a primary mouse antibody specific to the osteogenic marker type I 
collagen (provided by Larry Fischer, National Institute of Health, Bethesda, USA). 
Non-immunized rabbit IgG (DAKO) was used as an isotype control to rule out non-
specific reactions of rabbit IgG with rat tissues as well as non-specific binding of the 
secondary antibodies and/or peroxidase labelled polymer to rat tissues. The sections 
were incubated with the specific antibody or negative control in humidified chambers 
at 4°C over night. Sections were then washed three times for 2 min with Tris buffer 
(pH 7.4) and incubated with peroxidase labelled dextran polymer conjugated to goat 
anti-mouse and anti-rabbit immunoglobulins (DAKO EnVision+ Dual Link System 
Peroxidase, DAKO) at room temperature in humidified chambers for 60 min. Colour 
was developed using a liquid 3,3-diaminobenzidine (DAB) based system (DAKO). 
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Kaiser’s glycerol gelatin (DAKO) were used for coverslip mounting.  
 
 
2.9. Statistics 
Statistical analysis was performed for all the quantitative results using Student’s 
t-test for comparing means from two independent sample groups. A confidence 
level of 95% was used, statistical significance was set at p< 0.05. 
 
3. Results 
After 12 weeks, all groups were euthanized and the heads were removed for further 
evaluations. No wound infection or other complications occurred during the course of 
the experiment.  
 
3.2. MicroCT 
The bone regeneration capacity of scaffolds with different surface modifications and 
different laydown patterns were assessed in vivo after transplantation in a rat 
calvarial defect. Transplants were recovered after 12 weeks, subjected to micro-CT 
analysis and then processed for mechanical testing. Micro-CT analysis revealed a 
significantly higher degree of newly formed bone matrix in all experimental groups 
compared to the negative control group (empty defect) (Fig. 3). The empty defects 
remained primarily devoid of any mineralized tissue throughout the study, 
demonstrating they were of critical size (non-healing within the length of the study). 
The CHA-coated scaffolds with a 0/90° laydown pattern showed the highest amount 
of bone formation. Furthermore, all experimental groups treated with mPCL/TCP-
Scaffolds with a 0/90° laydown pattern of the fibres showed a tendency towards 
more bone formation compared to the mPCL/TCP-Scaffolds with a 0/60° 
configuration of the fibres. However, no significant difference could be found with 
regard to the mineral density of newly formed bone matrix (Fig. 3).  
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Fig 3.: MicroCT results of bone regeneration for all experimental groups. The 
bottom row shows representative 3D-reconstruction from the bone defects. All the 
experimental groups showed significantly more newly formed bone matrix within 
the defect compared to the empty groups (negative control). No significant 
differences could be detected between the experimental groups, whereas the 
mPCL/TCP-CHA-0/90° Scaffold-group showed the most bone formation of all 
groups. Furthermore, a tendency towards more bone formation in all the groups 
using the 0/90° pattern could be detected. Significant values are represented as *P 
< 0.05.  
 
 
3.3. Mechanical testing 
To test the mechanical integrity of the newly formed tissue within the scaffold pore 
space, micro-compression was performed on harvested calvaria at 8 different 
locations within the pore spaces of each scaffold (Figure 4A).  
The tissue stiffness of the mPCL/TCP-(si)-0/90° and the mPCL/TCP-(si)-CHA-0/90° 
showed the highest stiffness of all experimental groups. Interestingly, all defects 
treated with mPCL/TCP-Scaffolds with 0/90° laydown pattern of the fibres showed a 
tendency towards higher stiffness compared to the mPCL/TCP-0/60°-Scaffolds.  
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Push-out tests were performed to evaluate the mechanical integration of the 
constructs within the host calvaria, an important consideration from a craniofacial 
treatment point of view (Figure 4B). After 12 weeks, the defects treated with 
mPCL/TCP-(si)-0/90° Scaffolds, showed a comparable push-out strength to that of 
host bone tissue, suggesting new bone was forming from the periphery of the defect 
edges and encouraging integration of the implant within the defect site. All the other 
experimental groups showed significantly lower values for the push-out tests 
compared to the host bone. Within the experimental groups, we confirmed our 
observations from the previous analyses, that the mPCL-TCP-Scaffolds with the 
0/90° configuration of the fibres performed better, evidenced by higher push-out 
strengths, compared to the 0/60°-laydown pattern scaffolds.  
 
 
  
 
 
 
 
 
Fig. 4: Micro-compression tests were performed after 12 weeks (A). Stiffness of the samples within 
the defect is reported here. Regenerated tissue within the mPCL/TCP-(si)-0/90°-Scaffold group and 
the mPCL/TCP-(si)-CHA-0/90°-Scaffold group showed superior stiffness for all experimental groups. 
Significant values are represented as *P < 0.05. Push-out tests were performed after 12 weeks (B). 
Load of fracture of all samples are reported here. Regenerated tissue within the mPCL/TCP(si)-0/90°-
Scaffold group and the mPCL/TCP-(si)-CHA-0/90°-Scaffold group showed the highest push-out 
strength of all experimental groups. Significant values are represented as *P < 0.05.  
 
3.4. Histology 
Histological examination of decalcified samples was performed after 12 weeks. 
Representative H&E staining demonstrated clear defect bridging from the host bone 
with a good bonding of the scaffold in all experimental groups (Figure. 5). New bone 
formation is observed in all experimental groups adjacent to the host bone.  
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Notably, the mPCL-TCP-Scaffolds with the 0/90° configuration of the fibres revealed 
new bone formation adjacent to the implant struts (left as empty lacunae due to the 
dissolution of the PCL implant by xylene during processing) which penetrated to the 
middle of the defect, whereas the scaffolds with the 0/60° configuration of the fibres 
predominantly showed new bone formation closer to the host bone with less in the 
centre of the scaffold.  
 
 
 
 
 
 
Fig. 5: The overview of the defect treated with different scaffolds showed in the H&E staining a good 
bonding of the newly formed tissue to the host bone (HB)(bar in the overview=1mm). Arrows indicate 
the edges of host bone and the area of the higher magnification (bar=50µm). The higher 
magnifications demonstrated the ingrowth of new bone matrix from the host bone. The solvents used 
during the preparation of the histological sections resulted in the mPCL–TCP scaffold material being 
dissolved away during the embedding. Hence mPCL–TCP struts (S) are represented in histological 
sections as empty lacunas of similar geometry. 
 
New bone formation should be accompanied by the expression of osteogenic marker 
proteins, amongst these are type I collagen (Col-I), and osteocalcin (OC). 
Furthermore, markers of vascularity such as Von Willebrand factor (vWF) may be 
used to ascertain the vascularity at the defect site which is important to bring in 
nutrients and progenitor cells to the healing defect tissue. Figure 6 (A,B) shows 
entire defect/scaffold regions for both the 0/60/120° and 0/90° laydown patterns 
respectively with the magnified region probed for Col-I, OC and vWF (Figure 6 E-J). 
As a non-specific marker of osteoblastic differentiation during mineralisation, type I 
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collagen showed a greater intensity in the scaffold groups with the 0/90° laydown 
pattern compared to the 0/60/120° laydown pattern scaffolds, as shown in Figure 6 
E-H. Clear vascularity can also be detected in both groups (Figure 6 I,J). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Representative H&E staining of scaffolds with 0/60/120° and 0/90° configuration of the fibres 
(A-D). Col-I and OC staining is more prevalent in the groups with the 0/90° laydown pattern of the 
struts compared to the 0/60/120° scaffolds groups (E-H). All scaffold groups demonstrated 
vascularisation as evidenced by vWF staining (I,J). 
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4. Discussion 
A wide number of different biomaterials have been developed for cranial defects and 
are subject to intense current research efforts. There are two major engineering 
approaches to developing novel treatment concepts involving biomaterials: cell-
based and cell-free. In both cases, materials are engineered to provide optimal 
function for specific applications. In other words, scaffolds for cell-based therapies 
are intended to provide a compatible carrier for viable cells for enhanced 
histogenesis, function and integration within the recipient’s tissue bed. Scaffolds for 
cell-free repair are designed to stimulate neo-histogenesis, often by mimicking 
signals for anabolic processes. In the past, different scaffolds have been shown to 
be useful supports for the reconstruction of bone, however only a handful have 
brought fully satisfactory clinical results16. 
The philosophy of biomimetics has provided a new direction for biomaterial design. 
There are several different methods to influence and optimise the properties of the 
scaffold for bone tissue engineering such as different materials, different surface 
coatings, the pore size as well as the pore geometry. To improve integration of the 
scaffolds within the host site, they need to be resorbable and should have a porosity 
or favourable texture to enable good bonding with the surrounding tissue. Coatings 
and addition of bioactive molecules can also improve scaffold integration. These 
principles have been applied with varying success to musculoskeletal repair and 
reconstruction, but opportunities exist for more novel procedures17,18. 
The philosophy of biomimetics has provided a new direction for biomaterial design. 
In this study additive manufactured PCL/TCP(si) scaffolds coated with apatite were 
evaluated in vivo. The surface coated scaffolds demonstrated excellent results in 
previous in vitro studies7 but did not show the same trend in vivo compared to the 
uncoated scaffolds. Moreover, the CHA-gelatine coated scaffolds showed the least 
impressive mechanical properties and bone volume formation of all experimental 
groups. Though in vitro we have found significantly better results for the coated 
compared to the non-coated PCL/TCP(si) scaffolds, this did not translate to the in 
vivo situation. The surface coating of these scaffolds support the osteogenic 
differentiation of cells during in vitro conditions, but these effects were not sustained 
in an in vivo model. Clearly there are many different factors that influence bone 
 17 
regeneration in vivo and in vitro, and the complex interplay occurring in vivo is 
difficult to replicate within an in vitro research setting. In this study the differences 
between the surface coated groups and the uncoated scaffolds were more distinctive 
in the mechanical testing especially for the CHA and gelatine coated scaffolds. The 
surface modification with CHA and gelatine might lead to an appropriated bone 
formation within the pores, but the newly formed matrix may, in fact,  be connected 
to the gelatine coating and not to the scaffold itself. This might explain the major 
differences detected using mechanical tests. The difference in findings between in 
vitro and in vivo studies once again reminds us that, unfortunately, in vitro studies in 
isolation are not sufficient to predict the clinical outcome17. 
 
Beside the surface modification, the scaffolds had different configuration of their 
polycaprolactone fibres (0/90° and 0/60/120°). To our knowledge, no other group has 
reported differences in bone regeneration, with relation to the architecture of the 
struts in an in vivo model. In our study, the experimental groups with the 0/90° fibres 
alignment showed significantly higher bone regeneration potential compared to the 
0/60°-scaffold group, with respect to the newly formed bone matrix, the stiffness of 
the bone matrix and the maximum load of fracture. In the 0/90°-scaffold group, a 
better incorporation of cells from the host, as well as a better supply of nutrients 
might explain better bone regeneration. The different architecture of the struts also 
influenced the surface volume as well as the permeability of the scaffolds. Scaffolds 
with the 0/90° fibre alignment showed a significant higher porosity, a larger pore size, 
and a lower scaffold surface compared to the scaffolds with a 0/60° fibre alignment.  
Studies have demonstrated that pore size and porosity have an effect on bone tissue 
regeneration, with scaffold pore sizes required for bone regeneration ranging from 
100 to 500µm to allow micro vessel formation and a sufficient flow of nutrients to the 
interior of the scaffold9, 19.  
Roosa et al. showed in an in vivo model, that the pore size of polycaprolactone 
scaffolds had limited influence on bone regeneration8. Three different scaffolds with 
unique architecture and pore sizes of 350, 500, and 800µm were seeded with bone 
morphogenetic protein-7-transduced human gingival fibroblasts and implanted 
subcutaneously in immuno-compromised mice. They concluded the pore size played 
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a limited role in bone regeneration. Similar results were shown by Fisher et al.20, by 
implantation of scaffolds with different porosities and pore sizes subcutaneously and 
in cranial defects in rabbits, they also detected no statistical difference with respect 
to bone regeneration or inflammatory responses.  
 
In our current study all groups comprising scaffolds with a 0º/90° configuration of the 
fibres showed a tendency towards more bone formation, higher stiffness and higher 
push-out forces compared to the scaffolds with a 0º/60° configuration of the fibres. 
These results can therefore not only be explained by the differences in porosity, pore 
size and surface area. The architecture of the struts must also play an important role 
for new bone formation and integration of the newly formed tissue within the host 
bone, which also correlated with elevated mechanical properties.  
In conclusion, we have demonstrated that a surface modification of PCL-TCP 
scaffolds, which has shown increased osteogenic potential of scaffolds in vitro, did 
not translate into the in vivo situation using a rat cranial model. It showed minor 
regenerative potential regarding new bone formation as well as mechanical 
properties compared to uncoated scaffolds. In addition to studying the surface 
modification, we evaluated different architecture of the scaffold fibres with respect to 
their bone regeneration potential. From this perspective we can conclude, that a 
0/90°-alignment of the scaffold fibres demonstrated a significantly improved 
regeneration of bone tissue, meaning more bone formation with better mechanical 
properties in all experimental groups. In future it remains a challenge to optimise the 
many scaffold properties, which effect bone regeneration to produce an appropriate 
scaffold for bone tissue engineering applications,but considerations of scaffold 
architecture are clearly an important consideration. 
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